LCTX · Lineage Cell Therapeutics, Inc.
2 customers — 92% of revenue (the year ended December 31, 2025)
“For the year ended December 31, 2025, the Company’s top two customers collectively represented 92% of the Company’s total revenue.”
One customer — 92% of revenue (the year ended December 31, 2024)
“For the year ended December 31, 2024, the Company's top single customer represented 92% of the Company’s total revenue.”
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-08-06 |
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1) Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD |
| 2026-07-30 |
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
CARLSBAD, Calif. --(BUSINESS WIRE)--Jul. 30, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its second |
| 2026-07-13 |
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion |
| 2026-07-06 |
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
CARLSBAD, Calif. --(BUSINESS WIRE)--Jul. 6, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M. |
| 2026-05-12 |
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal Endothelial Disease Cell Therapy Program Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative Treated Second Chronic SCI Patient in OPC1 DOSED Device |
| 2026-05-05 |
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
CARLSBAD, Calif. --(BUSINESS WIRE)--May 5, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that it will report its first quarter 2026 |
| 2026-05-04 |
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
Gains in best corrected visual acuity (BCVA) of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the geographic atrophy (GA) lesion site OCT imaging indicated partial restoration of outer retinal structure, re-appearance of an RPE layer, and features |
| 2026-04-13 |
Lineage Announces Formation of Scientific Advisory Board
CARLSBAD, Calif. --(BUSINESS WIRE)--Apr. 13, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the formation of a Scientific |
| 2026-03-24 |
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted 10-Year CAGR of 7.7% CARLSBAD, Calif. --(BUSINESS WIRE)--Mar. |
| 2026-03-05 |
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Positive RG6501 (OpRegen ® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Achieved First Milestone Under Worldwide Collaboration with Genentech Based on RG6501 (OpRegen Cell Therapy) Program Manufacturing and Clinical Advancements |
| 2026-02-26 |
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
CARLSBAD, Calif. --(BUSINESS WIRE)--Feb. 26, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its fourth quarter |
| 2026-01-06 |
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
CARLSBAD, Calif. --(BUSINESS WIRE)--Jan. 6, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today announced the receipt of a novel, induced |
| 2026-01-05 |
Lineage Cell Therapeutics Issues Letter to Stockholders
CARLSBAD, Calif. --(BUSINESS WIRE)--Jan. 5, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today published a letter to shareholders |
| 2025-11-24 |
Lineage Achieves First Milestone Under Worldwide Collaboration Agreement with Genentech
LINEAGE ACHIEVES FIRST MILESTONE UNDER WORLDWIDE COLLABORATION AGREEMENT WITH GENENTECH November 24, 2025 Lineage Cell Therapeutics, Inc. today announced it had achieved the first milestone available under its worldwide collaboration with Roche and Genentech , a member of the Roche Group, for |